An increasing focus on advanced imaging and diagnostic solutions is driving Singapore’s medical device sector to integrate artificial intelligence (AI) in routine clinical practice. The sector’s development is in line with the country’s goal of a ‘future-ready’ healthcare system capable of meeting rising demand and complexity, according to a GlobalData report. A key development is the US-based medical technology company Intelligent Scopes Corp securing regulatory approval from the Health Sciences Authority (HSA) for its AI-powered software tool, CystoSmart, which supports bladder cancer detection. The tool analyses cystoscopy images to help clinicians detect and characterise lesions, reducing variability in interpretation while leaving final decisions to the clinician. https://sbr.com.sg/healthcare/news/hsa-clears-cancer-detecting-ai-routine-hospital-use   (ICE SINGAPORE)

Fonte notizia: Singapore Business Review, 28 January 2026